News
Public · Published
Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study
Alamar Biosciences and Nightingale Health announced the launch of a UK Biobank study involving 80,000 blood samples. Nightingale's laboratories will use Alamar's NULISA platform to measure hundreds of blood-based protein biomarkers linked to Parkinson's disease, Alzheimer's disease and other neurodegenerative conditions.
Published:
Updated:
What happened
Alamar Biosciences and Nightingale Health announced the launch of a UK Biobank study involving 80,000 blood samples. Nightingale’s laboratories will use Alamar’s NULISA platform to measure hundreds of blood-based protein biomarkers linked to Parkinson’s disease, Alzheimer’s disease and other neurodegenerative conditions.
Confirmed
Global impact / market context
The study could help researchers identify molecular signs of brain disease earlier, potentially supporting future prevention and treatment research. For the companies, running the project may demonstrate their ability to process large research studies, although the article gives no commercial terms or expected revenue.
Analyst inference
The project combines Alamar’s protein-measurement platform with Nightingale’s laboratory work and UK Biobank samples. Its stated output is an open-access research resource, so the article describes a scientific collaboration rather than a confirmed product launch, customer contract value, or near-term sales contribution.
Analyst inference
What to watch
- Watch for details on when testing begins and how the 80,000 samples will be processed; the article announces the study launch but gives no timetable. Analyst inference
- Look for published findings on whether the measured proteins help identify neurodegenerative disease earlier or distinguish Parkinson’s, Alzheimer’s and other conditions. Analyst inference
- The article says findings will create a large open-access resource; check when researchers can access it and what results are made available. Confirmed
Evidence
- Original source link unavailable